Oxford Covid-19 vaccine may resume trials next week
The London-listed firm had to pause global trials of its potential vaccine for Covid-19 after an unexplained illness in a participant, which sent its shares lower as the move was seen as dimming prospects for an early rollout
File Photo: Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo
British drugmaker AstraZeneca Plc could resume trials for its experimental coronavirus vaccine next week, the Financial Times reported on Wednesday, citing people associated with the trials.
The London-listed firm had to pause global trials of its potential vaccine for Covid-19 after an unexplained illness in a participant, which sent its shares lower as the move was seen as dimming prospects for an early rollout.
AstraZeneca did not immediately respond to a Reuters request for comment.
Keep updated, follow The Business Standard's Google news channel
The vaccine, which AstraZeneca is developing with the University of Oxford, has been described by the World Health Organization (WHO) as probably the world's leading candidate and the most advanced in terms of development.
